Literature DB >> 22277146

Hydralazine-induced lupus erythematosis.

Joel Handler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22277146      PMCID： PMC8108775          DOI： 10.1111/j.1751-7176.2011.00573.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  18 in total

1.  Fulminating hydralazine-induced lupus pneumonitis.

Authors:  Belinda Birnbaum; Gurdip S Sidhu; Robert L Smith; Michael H Pillinger; Clement E Tagoe
Journal:  Arthritis Rheum       Date:  2006-06-15

2.  Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.

Authors:  N Sangala; R W Lee; C Horsfield; D J A Goldsmith
Journal:  Int Urol Nephrol       Date:  2009-08-15       Impact factor: 2.370

Review 3.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

Review 4.  Drug-induced lupus: an update.

Authors:  Uriel Katz; Gisele Zandman-Goddard
Journal:  Autoimmun Rev       Date:  2010-07-23       Impact factor: 9.754

5.  Do selected drugs increase the risk of lupus? A matched case-control study.

Authors:  W Marieke Schoonen; Sara L Thomas; Emily C Somers; Liam Smeeth; Joseph Kim; Stephen Evans; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 6.  Drug-induced lupus: an update on its dermatologic aspects.

Authors:  A V Marzano; P Vezzoli; C Crosti
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

7.  Antibodies to the five histones and poly(adenosine diphosphate-ribose) in drug induced lupus: implications for pathogenesis.

Authors:  R N Hobbs; A L Clayton; R M Bernstein
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

Review 8.  Drug-induced lupus erythematosus.

Authors:  Camilla Dalle Vedove; Micol Del Giglio; Donatella Schena; Giampiero Girolomoni
Journal:  Arch Dermatol Res       Date:  2008-09-17       Impact factor: 3.017

Review 9.  Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.

Authors:  Shannon W Finks; A Lloyd Finks; Timothy H Self
Journal:  South Med J       Date:  2006-01       Impact factor: 0.954

10.  Hydralazine, antinuclear antibodies, and the lupus syndrome.

Authors:  R Mansilla-Tinoco; S J Harland; P J Ryan; R M Bernstein; C T Dollery; G R Hughes; C J Bulpitt; A Morgan; J M Jones
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27
View more
  7 in total

1.  SLE or hypothyroidism: who can triumph in cardiac tamponade?

Authors:  Sameer Sadashiv Chaudhari; Kashmira Pramod Wankhedkar; Savi Mushiyev
Journal:  BMJ Case Rep       Date:  2015-03-06

Review 2.  The management of hypertension in pregnancy.

Authors:  Andrea G Kattah; Vesna D Garovic
Journal:  Adv Chronic Kidney Dis       Date:  2013-05       Impact factor: 3.620

3.  Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.

Authors:  Praneet Iyer; Ahmed Dirweesh; Ritika Zijoo
Journal:  Case Rep Rheumatol       Date:  2017-01-17

4.  Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis.

Authors:  Sarah K Holman; Donique Parris; Sarah Meyers; Jason Ramirez
Journal:  Case Rep Pulmonol       Date:  2017-08-08

5.  ANA-Negative Hydralazine-Induced Pericardial Effusion.

Authors:  Vicken Zeitjian; Azar Mehdizadeh
Journal:  Case Rep Med       Date:  2017-12-17

Review 6.  Orofacial manifestations of adverse drug reactions: a review study.

Authors:  Sedigheh Bakhtiari; Marziye Sehatpour; Hamed Mortazavi; Mahin Bakhshi
Journal:  Clujul Med       Date:  2018-01-15

7.  Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?

Authors:  Erika Aurora Martínez-García; Maria Guadalupe Zavala-Cerna; Andrea Verónica Lujano-Benítez; Pedro Ernesto Sánchez-Hernández; Beatriz Teresita Martín-Márquez; Flavio Sandoval-García; Mónica Vázquez-Del Mercado
Journal:  Front Immunol       Date:  2018-07-06       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.